Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

AstraZeneca Receives European Approval for VIMOVO

By Pharmaceutical Processing | October 11, 2010

AstraZeneca and POZEN Inc. today announced that VIMOVO (naproxen/
esomeprazole magnesium) 500/20 mg modified-release tablets has cleared
an important regulatory milestone by receiving positive agreement for
approval in 23 countries across the European Union (EU). This follows
all 22 Concerned Member States agreeing with the assessment of the
Netherlands Health Authority (MEB), acting as the Reference Member State
for the Decentralised Procedure (DCP).  It also results in a harmonised
Summary of Product Characteristics (SmPC). The Member States will now
pursue pricing and reimbursement and national approvals.

 

VIMOVO
is indicated for the symptomatic treatment of osteoarthritis (OA),
rheumatoid arthritis (RA), and ankylosing spondylitis (AS) in patients
who are at risk for developing non-steroidal anti-inflammatory drug
(NSAID)-associated gastric and/or duodenal ulcers and where treatment
with lower doses of naproxen or of other NSAIDs is not considered
sufficient.

 

VIMOVO, co-developed by AstraZeneca and POZEN Inc., is
a fixed-dose combination of enteric-coated naproxen, a pain-relieving
NSAID, and immediate-release esomeprazole, a proton pump inhibitor
(PPI). The positive agreement is based on a submission package including
data from the pivotal trials PN400-301 and PN400-302, which
demonstrated that patients taking VIMOVO experienced significantly fewer
endoscopic gastric ulcers, compared to patients receiving
enteric-coated naproxen.

 

“This support for the approval of VIMOVO
in Europe is a significant milestone, which we believe will provide a
new treatment option for the millions of arthritis patients in the EU at
risk for NSAID-associated ulcers,” said Lori Kreamer, Global Products
Vice President, AstraZeneca. “In one tablet, VIMOVO offers the proven
pain relief of naproxen with built-in ulcer risk reduction.” 

Nearly
151 million people worldwide and approximately 28 million people in
Europe suffer from OA, which is the most common form of arthritis. 
While many patients with OA treat their symptoms with NSAIDs, 50% of
chronic NSAID users are at risk of gastrointestinal ulcers.

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards